Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and Erlotinib in Relapsed/Refractory NSCLC
NCT00251589Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Primary completion
- Oct 2007
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, open-label trial of vorinostat in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Merck & Co. Primary endpoint: Dose Limiting Toxicity. Started Jan 2006; status: terminated.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00251589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251589.